Business Context and Reporting Period
This Form 6-K filing by Smith & Nephew plc is dated November 11, 2024. The document serves as a notification and public disclosure under the EU Market Abuse Regulation regarding transactions by Persons Discharging Managerial Responsibilities (PDMR) and persons closely associated with them.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively reports on share transactions.
| Instrument | Transaction Type | Date | Price (USD) | Total Volume (Shares) |
|---|---|---|---|---|
| Ordinary Shares (ISIN: GB0009223206) | Purchase via Dividend Re-Investment Plan | November 8, 2024 | 9.234 | 3,548.856 |
Note: Total volume is the aggregate of individual transactions listed below.
Material Changes
The filing details a single type of transaction: the purchase of ordinary shares by six executives through the Company's Dividend Re-Investment Plan following the 2024 interim dividend payment. There are no material changes to the company's business operations or financial position reported in this document.
Guidance, Outlook, and Risks
This filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory compliance document regarding insider trading disclosures.
Important Facts for Investors
- Transaction Nature: All reported transactions were purchases made via the Dividend Re-Investment Plan, not open market trades.
- Participants: Transactions were executed by CEO Deepak Nath, President of Sports Medicine Scott Schaffner, President of Global Operations Paul Connolly, Group General Counsel Helen Barraclough, Chief Corporate Development Officer Phil Cowdy, and Chief Quality & Regulatory Affairs Officer Mizanu Kebede.
- Transaction Price: All shares were purchased at a uniform price of $9.234 per share.
- Largest Transaction: CEO Deepak Nath purchased the largest volume of shares (1,924.21 shares).
- Financial Data: This document provides no data on the company's financial health, revenue, or earnings.